- Conditions
- Contrast Induced Nephropathy (CIN)
- Interventions
- AVERT
- Device
- Lead sponsor
- Osprey Medical, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 578 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 37
- States / cities
- La Jolla, California • Long Beach, California • Los Angeles, California + 29 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 721–744
of 1,820
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Educational Activities
- Interventions
- Text Messaging Only, INFORMED
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 247 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Fresno, California • San Francisco, California • San Jose, California
- Conditions
- Kidney Failure, Acute
- Interventions
- Not listed
- Lead sponsor
- Abbott RDx Cardiometabolic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 355 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 10
- States / cities
- Denver, Colorado • Washington D.C., District of Columbia • Portland, Maine + 6 more
- Conditions
- Colorectal Cancer
- Interventions
- small media, group education (multicomponent)
- Behavioral
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 50 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Plaque
- Interventions
- Comparison Condition, BeReady2Smile video only, BeReady2Smile video and BeReady2Smile app completely self-guided, "Complete" BeReady2Smile video and BeReady2Smile app guided by a Coach
- Behavioral
- Lead sponsor
- Oregon Research Behavioral Intervention Strategies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Springfield, Oregon
- Conditions
- Intraocular Melanoma, Melanoma (Skin)
- Interventions
- lomustine, temozolomide, thalidomide
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- HIV Infections, Sexually Transmitted Diseases
- Interventions
- PrEPmate, Dot Diary
- Other · Device
- Lead sponsor
- Public Health Foundation Enterprises, Inc.
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Miami, Florida
- Conditions
- Alopecia
- Interventions
- Hair Stimulating Complex (HSC), Phosphate Buffered Saline
- Biological · Other
- Lead sponsor
- Histogen
- Industry
- Eligibility
- 40 Years to 70 Years · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Healthy
- Interventions
- Pregabalin controlled release, 330 mg, low-fat, Pregabalin controlled release, 330 mg, medium-fat, Pregabalin controlled release, 330 mg, high-fat, Pregabalin immediate release, 300 mg
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Otitis Media With Effusion in Children, Otitis Media Recurrent
- Interventions
- EXE844 Sterile Otic Suspension, 0.3%, Tympanostomy Tube Insertion
- Drug · Procedure
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 6 Months to 12 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Brain Tumor, Brain Necrosis, Brain Metastases, Glioma
- Interventions
- MRF in conjunction with IVIM MRI without contrast
- Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio
- Conditions
- Pediatric Obesity, Obesity
- Interventions
- Parents Connect for Healthy Living (PConnect), Enhanced Nutrition Support, Media Resources
- Behavioral
- Lead sponsor
- Boston College
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 4,999 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Chestnut Hill, Massachusetts
- Conditions
- Feeding Behaviors
- Interventions
- Varying meal energy density and portion size
- Other
- Lead sponsor
- Penn State University
- Other
- Eligibility
- 3 Years to 6 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2013
- U.S. locations
- 1
- States / cities
- University Park, Pennsylvania
- Conditions
- Acute Otitis Media
- Interventions
- Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 6 Months to 4 Years
- Enrollment
- 318 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Hypercholesterolemia, Coronary Heart Disease
- Interventions
- Different amount of phytosterols are added into diets
- Dietary Supplement
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Recurrent Acute Otitis Media, Acute Otitis Media
- Interventions
- EarPopper
- Device
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 4 Years to 11 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Mucinous Adenocarcinoma, Recurrent Fallopian Tube Transitional Cell Carcinoma, Recurrent Fallopian Tube Undifferentiated Carcinoma, Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Ovarian Mucinous Adenocarcinoma, Recurrent Ovarian Seromucinous Carcinoma, Recurrent Ovarian Transitional Cell Carcinoma, Recurrent Ovarian Undifferentiated Carcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Transitional Cell Carcinoma, Recurrent Primary Peritoneal Undifferentiated Carcinoma, Refractory Fallopian Tube Clear Cell Adenocarcinoma, Refractory Fallopian Tube Endometrioid Adenocarcinoma, Refractory Fallopian Tube High Grade Serous Adenocarcinoma, Refractory Fallopian Tube Mucinous Adenocarcinoma, Refractory Fallopian Tube Transitional Cell Carcinoma, Refractory Fallopian Tube Undifferentiated Carcinoma, Refractory Low Grade Fallopian Tube Serous Adenocarcinoma, Refractory Ovarian Clear Cell Adenocarcinoma, Refractory Ovarian Endometrioid Adenocarcinoma, Refractory Ovarian High Grade Serous Adenocarcinoma, Refractory Ovarian Low Grade Serous Adenocarcinoma, Refractory Ovarian Mucinous Adenocarcinoma, Refractory Ovarian Seromucinous Carcinoma, Refractory Ovarian Transitional Cell Carcinoma, Refractory Ovarian Undifferentiated Carcinoma, Refractory Primary Peritoneal Clear Cell Adenocarcinoma, Refractory Primary Peritoneal Endometrioid Adenocarcinoma, Refractory Primary Peritoneal High Grade Serous Adenocarcinoma, Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma, Refractory Primary Peritoneal Transitional Cell Carcinoma, Refractory Primary Peritoneal Undifferentiated Carcinoma
- Interventions
- Biospecimen Collection, Cediranib Maleate, Computed Tomography, Computed Tomography with Contrast, Durvalumab, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 384
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 288 more
- Conditions
- Small Cell Lung Carcinoma (SCLC)
- Interventions
- BI 764532, Carboplatin, Etoposide, Atezolizumab
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Atlanta, Georgia
- Conditions
- Gyrate Atrophy, Gyrata of Choroid and Retina; Atrophy, Ornithine-δ-aminotransferase, OAT, Chorioretinal Degeneration
- Interventions
- Not listed
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 4
- States / cities
- San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
- Conditions
- Smoking Cessation
- Interventions
- Quitxt text messaging or Chat, Usual care
- Behavioral · Other
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 29 Years
- Enrollment
- 1,200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Infertility, Reproductive Techniques, Assisted
- Interventions
- Embryo Culture medium
- Device
- Lead sponsor
- National Foundation for Fertility Research
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 2
- States / cities
- Lone Tree, Colorado
- Conditions
- Parkinson's Disease
- Interventions
- Deep Brain Stimulation
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 22 Years to 75 Years
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 18 more
- Conditions
- Healthy Subjects
- Interventions
- Placebo, mirabegron, moxifloxacin
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 352 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 2
- States / cities
- Glendale, California • Baltimore, Maryland
- Conditions
- Healthy Volunteers
- Interventions
- AZD4205, Placebo
- Drug
- Lead sponsor
- Dizal Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Secaucus, New Jersey